NCT04901299 2023-08-01
HER2-Signal
Massachusetts General Hospital
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT04781374 2023-07-11
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
Beth Israel Deaconess Medical Center
Phase 2 Withdrawn
NCT04856475 2022-03-02
NeraBrain
Jules Bordet Institute
Phase 2 Withdrawn
NCT01960023 2021-10-27
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
NSABP Foundation Inc
Phase 1/2 Withdrawn